WallStSmart

Align Technology Inc (ALGN)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 1286% more annual revenue ($57.36B vs $4.14B). NVS leads profitability with a 17.5% profit margin vs 10.0%. ALGN appears more attractively valued with a PEG of 0.64. ALGN earns a higher WallStSmart Score of 56/100 (C).

ALGN

Buy

56

out of 100

Grade: C

Growth: 3.3Profit: 6.5Value: 8.0Quality: 7.0
Piotroski: 4/9Altman Z: 2.76

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALGNUndervalued (+32.3%)

Margin of Safety

+32.3%

Fair Value

$291.64

Current Price

$166.00

$125.64 discount

UndervaluedFair: $291.64Overvalued
NVSSignificantly Overvalued (-68.3%)

Margin of Safety

-68.3%

Fair Value

$95.56

Current Price

$161.93

$66.37 premium

UndervaluedFair: $95.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALGN3 strengths · Avg: 8.7/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.648/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

NVS4 strengths · Avg: 9.5/10
Market CapQuality
$303.67B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

ALGN2 concerns · Avg: 3.0/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

EPS GrowthGrowth
-12.1%2/10

Earnings declined 12.1%

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.2x4/10

Trading at 8.2x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ALGN

The strongest argument for ALGN centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.64 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.

Bear Case : ALGN

The primary concerns for ALGN are Revenue Growth, EPS Growth.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

ALGN carries more volatility with a beta of 1.67 — expect wider price swings.

NVS is growing revenue faster at 4.7% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALGN scores higher overall (56/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Align Technology Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Align Technology is a manufacturer of 3D digital scanners and the Invisalign clear aligners used in orthodontics. It is headquartered in San Jose, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?